Fresenius Medical Care AG & Co. KGaA (NYSE: FMS- Get a rating) announced an annual dividend on Friday, April 29, the wall street journal reports. Shareholders of record on Monday, May 16 will receive a dividend of 0.7093 per share on Friday, May 27. This represents a dividend yield of 3.4%. The ex-dividend date is Friday, May 13.
Fresenius Medical Care AG & Co. KGaA has a payout ratio of 33.7%, indicating that its dividend is sufficiently covered by earnings. Research analysts expect Fresenius Medical Care AG & Co. KGaA to earn $2.34 per share next year, meaning the company should continue to be able to cover its $0 annual dividend. $82 with an expected future payout ratio of 35.0%.
FMS stock was down $0.75 in Friday trading, hitting $30.93. The company had a trading volume of 352,160 shares, compared to an average volume of 508,459. The company has a market capitalization of $18.12 billion, a PE ratio of 16.16, a price-to-earnings growth ratio of 1.54 and a beta of 1.20. Fresenius Medical Care AG & Co. KGaA has a 1 year minimum of $28.75 and a 1 year maximum of $42.45. The company has a 50-day moving average price of $32.71 and a 200-day moving average price of $32.86. The company has a quick ratio of 0.82, a current ratio of 1.10 and a leverage ratio of 0.48.
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) last released its quarterly results on Tuesday, February 22. The company reported earnings per share (EPS) of $0.51 for the quarter, beating Thomson Reuters consensus estimate of $0.50 by $0.01. The company posted revenue of $5.31 billion for the quarter, versus $5.38 billion expected by analysts. Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 7.51% and a net margin of 5.51%. Sell-side analysts expect Fresenius Medical Care AG & Co. KGaA to post earnings per share of 2.08 for the current year.
Several equity analysts have recently published reports on FMS stocks. Societe Generale lowered its price target on Fresenius Medical Care AG & Co. KGaA from €61.00 ($65.59) to €57.00 ($61.29) in a Friday, February 25 research report. Oddo Bhf has upgraded Fresenius Medical Care AG & Co. KGaA from a ‘neutral’ rating to an ‘outperforming’ rating and set a price target of €72.00 ($77.42) on the stock in a report Tuesday, March 1. Jefferies Financial Group downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to an “underperform” rating and lowered its price target for the company from $32.40 to $30.30 in a report from the Friday February 11. Zacks Investment Research upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating and set a price target of $35.00 on the stock in a Tuesday, January 11 report. Finally, Berenberg Bank lowered its price target on Fresenius Medical Care AG & Co. KGaA from €84.90 ($91.29) to €83.40 ($89.68) in a Thursday, March 17 report. Two equity research analysts gave the stock a sell rating, eight gave the company a hold rating and six gave the company a buy rating. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $51.71.
Several large investors have recently changed their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 2.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 514,568 shares of the company worth $16,703,000 after acquiring an additional 14,491 shares last quarter. DE Shaw & Co. Inc. acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q4, valued at approximately $2,398,000. Bank of New York Mellon Corp increased its stake in Fresenius Medical Care AG & Co. KGaA by 9.5% in Q3. Bank of New York Mellon Corp now owns 25,989 shares of the company valued at $909,000 after buying 2,252 additional shares last quarter. Cubist Systematic Strategies LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q4 valued at approximately $730,000. Finally, Citadel Advisors LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 8.2% in the 2nd quarter. Citadel Advisors LLC now owns 20,662 shares of the company valued at $859,000 after purchasing an additional 1,558 shares last quarter. 4.89% of the shares are currently held by institutional investors and hedge funds.
Fresenius Medical Care AG & Co. KGaA Company Profile (Get a rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]t.com.
Should you invest $1,000 in Fresenius Medical Care AG & Co. KGaA right now?
Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.
While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here